Chemerin induces endothelial cell inflammation: activation of nuclear factor-kappa beta and monocyte-endothelial adhesion. by Dimitriadis, Georgios K et al.
Oncotarget16678www.oncotarget.com
Chemerin induces endothelial cell inflammation: activation of 
nuclear factor-kappa beta and monocyte-endothelial adhesion
Georgios K. Dimitriadis1,2,3,*, Jaspreet Kaur1,4,*, Raghu Adya1, Alexander D. Miras2, 
Harman S. Mattu1, John G. Hattersley3, Gregory Kaltsas3, Bee K. Tan1,5 and Harpal 
S. Randeva1,3,6
1Division of Translational and Experimental Medicine, Warwick Medical School, University of Warwick, Coventry, UK
2Division of Endocrinology and Experimental Medicine, Imperial College London, Hammersmith Campus, London, UK
3WISDEM Centre, Human Metabolism Research Unit, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
4Division of Biomedical Sciences, School of Medicine, University of California, Riverside, CA, USA
5Department of Obstetrics and Gynaecology, Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, 
Birmingham, UK
6Division of Life and Health Sciences, Aston University, Birmingham, UK
*These are joint first authors
Correspondence to: Harpal S. Randeva, email: Harpal.Randeva@warwick.ac.uk
Keywords: chemerin; T2DM; atherosclerosis; endothelium; inflammation
Received: January 15, 2018    Accepted: February 27, 2018    Published: March 30, 2018
Copyright: Dimitriadis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
Chemerin, a chemoattractant protein, acts via a G-protein coupled chemokine 
receptor, i.e. Chemokine like Receptor 1/ChemR23; levels of which are elevated 
in pro-inflammatory states such as obesity and type 2 diabetes mellitus (T2DM). 
Obesity and T2DM patients are at high risk of developing cardiovascular disorders 
such as atherosclerosis. We have reported that chemerin induces human endothelial 
cell angiogenesis and since dysregulated angiogenesis and endothelial dysfunction 
are hallmarks of vascular disease; we sought to determine the effects of chemerin 
on monocyte-endothelial adhesion, and nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB), a critical pro-inflammatory transcription factor. Human 
endothelial cells were transfected with pNF-kappaB-Luc plasmid. Chemerin induced 
NF-κB activation via the MAPK and PI3K/Akt pathways. Western blot analyses and 
monocyte-endothelial adhesion assay showed that chemerin increased endothelial 
cell adhesion molecule expression and secretion, namely E-selectin (Endothelial 
Selectin), VCAM-1 (Vascular Cell Adhesion Molecule-1) and ICAM-1 (Intracellular 
Adhesion Molecule-1), leading to enhancement of monocyte-endothelial adhesion. 
Additionally, we showed a synergistic response of the pro-inflammatory mediator, 
Interleukin-1β with chemerin induced effects. Chemerin plays an important role in 
endothelial inflammation, as it induces monocyte-endothelial adhesion, a critical step 
in the development of atherosclerosis.
INTRODUCTION
Obesity, characterised as a state of chronic low grade 
systemic inflammation, is recognised as an independent 
risk factor for cardiovascular morbidity and mortality 
and a significant contributor to the pathogenesis of 
atherosclerosis [1]. Interactions between endothelial cells 
and circulating monocytes, in co-existing arterial wall 
dysfunction and systemic inflammation, are hallmarks 
of this complex pathophysiological process [2]. Various 
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adipose tissue derived bio-active molecules (adipokines) 
have been implicated in the maintenance of vascular 
homeostasis including expression and engagement of 
adhesion molecule receptors on both endothelial cells 
and monocytes such as E-selectin (endothelial selectin), 
vascular cell adhesion molecule 1 (VCAM-1) and 
intercellular adhesion molecule-1 (ICAM-1) [3]. Altered 
circulating adipokine concentrations have been reported 
in obese, insulin resistant subjects with T2DM [4–7]. 
Activation of these endothelial adhesion molecules via 
the NF-кB pathway is an important step in vascular 
inflammation and the development of atherosclerosis [8].
A recently discovered adipokine, chemerin, 
functions as a chemo-attractant protein, mediating its 
effects through a G-protein Coupled Receptor, Chemokine 
like Receptor 1, also known as ChemR23 [9]. Increased 
circulating levels of chemerin are found in obesity, 
exhibiting positive correlations with various aspects of 
the metabolic syndrome [10]. Studies have implicated 
the role of chemerin and Chemokine like Receptor 1 
in the recruitment of immune cells in inflammatory 
and auto-immune disorders [11]. More importantly 
Spiroglou et al. have demonstrated increased periaortic 
and pericoronary adipose tissue expression levels of 
chemerin in patients with atherosclerosis, suggesting a 
possible paracrine mediated effect [12]. Additionally, 
we have previously demonstrated the pro-angiogenic 
effects of chemerin [13]. Dysregulated angiogenesis, 
in particular plaque neovascularisation, is a recognised 
contributor to symptomatic atherosclerosis [14]. NF-B is 
a major transcription factor in inflammatory responses, 
regulating a plethora of genes, pivotal in the initiation 
and progression of vascular inflammation [15]. Therefore, 
we investigated the effects of chemerin on monocyte-
endothelial interaction, the involvement of endothelial 
specific adhesion molecules and the participation of NF-
кB, MAPK and PI3Akt pathways.
RESULTS
Chemerin activates NF-кB in HMEC-1 cells via 
MAPK and PI3K/Akt pathways; synergistic 
activation with IL-1β
We employed a NF-кB-Luc plasmid, stably 
transfected Human Microvascular Endothelial Cell 
(HMEC)-1 cell line to investigate the role of NF-кB in 
the development of vascular inflammation. Our findings 
were that chemerin treatment increased the luciferase 
activity in a concentration-dependent manner after 2 
hours of incubation (Figure 1: **P < 0.01 vs. basal, ***P < 
0.001 vs. basal). However, when pre-incubated with BAY 
11-7085 [(10μM), NF-ĸB inhibitor] or U0126 [(10μM), 
MAPK inhibitor] or SB202190 [(1 μM), p38 MAPK 
inhibitor] or LY294002 [(10 μM), PI3K/Akt inhibitor] for 
1 hour, chemerin induced (10nM) NF-B activation was 
significantly attenuated [Figure 1: #P < 0.001 vs. chemerin 
(10nM) only treated]. Furthermore, when chemerin 
(10nM) was co-incubated with IL-1β (0-100ng/mL), a 
significant increase in NF-B activity was observed [Figure 
1: aP < 0.05, bP < 0.01, cP < 0.001 vs. IL-1β (100ng/mL) 
only treated, P < 0.001 vs. chemerin (10nM) only treated].
Chemerin increases endothelial cell adhesion 
molecules mRNA, protein expression and 
secretion in HMEC-1 cells
Increased expression of endothelial cell adhesion 
molecules are hallmarks of vascular inflammation and 
atherosclerosis [19]. Serum starved HMEC-1 cells were 
stimulated with chemerin (R&D; 0-10nM) for 4, 12 and 24 
hours, following initial concentration and time dependent 
optimisation experiments (data not shown). Real-time 
quantitative RT-PCR analyses showed that mRNA 
expression of E-selectin, VCAM-1 and ICAM-1, were 
significantly up-regulated by chemerin in a concentration 
dependent manner at 4 hours (Figures 2A-2C: ***P < 0.001 
vs. basal). Also, western blotting analyses of HMEC-
1 cell protein lysates showed that protein expression of 
E-selectin, VCAM-1 and ICAM-1, were significantly 
increased in a concentration dependent manner at 12 
hours (Figures 3A-3C: *P < 0.05 vs. basal, ***P < 0.001 vs. 
basal) and 24 hours (Figures 3D-3F: *P < 0.05 vs. basal, 
**P < 0.01 vs. basal, ***P < 0.001 vs. basal). Furthermore, 
western blotting analyses of HMEC-1 cell conditioned 
media showed that secretion of E-selectin, VCAM-1 and 
ICAM-1, were significantly elevated by chemerin in a 
concentration dependent manner at 12 hours (Figures 4A-
4C: *P < 0.05 vs. basal, **P < 0.01 vs. basal, ***P < 0.001 
vs. basal) and 24 hours (data not shown).
Chemerin and IL-1β co-incubation; synergistic 
increase in cell adhesion molecule expression
Serum starved HMEC-1 cells were stimulated with 
chemerin (3nM) with or without IL-1β (10ng/ml) for 12 
hours, following initial concentration and time dependent 
optimisation experiments (data not shown); western 
blotting analyses of HMEC-1 cell protein lysates showed 
that protein expression of E-selectin, VCAM-1 and 
ICAM-1, were synergistically increased when compared 
to chemerin or IL-1β alone (Figures 5A-5D: ***P < 0.001 
vs. basal, *P < 0.05 vs. chemerin or IL-1β alone, **P < 
0.01 vs. chemerin or IL-1β alone). In addition, when pre-
incubated with BAY 11-7085 [(10μM), NF-ĸB inhibitor], 
chemerin (3nM) induced VCAM-1 protein expression 
was significantly attenuated, indicating the potential role 
of NF-ĸB in chemerin induced cell adhesion molecule 
expression (Figure 5E: ***P < 0.001). Furthermore, 
densitometric analysis of western blots from starved 
HMEC-1 treated with chemerin (0-10nM) cells, revealed 
significantly elevated secretion of E-selectin, VCAM-1 
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and ICAM-1, in a concentration dependent manner at 12 
hours (Figures 4A-4C: *P < 0.05 vs. basal, **P < 0.01 vs. 
basal, ***P < 0.001 vs. basal).
Chemerin stimulates monocyte-endothelial 
cell adhesion via NF-ĸB, MAPK and PI3K/Akt 
pathways
Given that monocyte-endothelial interactions 
play a pivotal role in endothelial inflammation and the 
development of atherosclerosis [2], we assessed the 
effects of chemerin on monocyte-endothelial adhesion in 
vitro. Serum starved chemerin (0-10nM) treated HMEC-1 
cells were co-cultured with Human Monocytic Leukemia 
Cells (THP-1) for 2 hours. Chemerin enhanced monocyte-
endothelial adhesion in a concentration dependent fashion 
(Figure 6A: *P < 0.05 vs. basal, **P < 0.01 vs. basal). 
Furthermore, pre-incubation for 1 hour with BAY 11-7085 
[(10μM), NF-ĸB inhibitor] or U0126 [(10μM), MAPK 
inhibitor] or SB202190 [(1 μM), p38 MAPK inhibitor] 
or LY294002 [(10 μM), PI3K/Akt inhibitor], prior to 
treatment with chemerin (10nM) for 2 hours, chemerin 
induced monocyte-endothelial adhesion was significantly 
ameliorated [Figure 6A: *P < 0.05 vs. chemerin (10nM) 
only treated, **P < 0.01 vs. chemerin (10nM) only 
treated], thereby implicating the role of NF-ĸB, MAPK 
and PI3K/Akt pathways in chemerin induced monocyte-
endothelial adhesion. These results were further confirmed 
by fluorescent microscopy and images were transferred 
using National Institutes of Health (USA) ImageJ software 
(Figure 6B).
DISCUSSION
Studies have supported an important role for 
chemerin in the pathophysiological processes involved 
in obesity and diabetes [10–13]. Clinical reports show 
elevated circulating levels of chemerin in these states with 
Figure 1: Chemerin activates NF-кB in HMEC-1 cells via MAPK and PI3K/Akt pathways; synergistic activation 
with IL-1β pathways. Serum starved HMEC-1 cells stably transfected with pNFкB-Luciferase were treated with or without chemerin 
(0-10nM) for 2 hours. Cells were lysed and luciferase activities were measured. Chemerin induced a concentration dependent increase in 
luciferase activity after 2 hours of incubation (**P < 0.01 vs. basal, ***P < 0.001 vs. basal). When pre-incubated with BAY 11-7085 [(10μM), 
NF-ĸB inhibitor] or U0126 [(10μM), MAPK inhibitor] or SB202190 [(1 μM), p38 MAPK inhibitor] or LY294002 [(10 μM), PI3K/Akt 
inhibitor] for 1 hour, chemerin induced (10nM) NF-B activation was significantly attenuated (#P < 0.001 vs. chemerin (10nM) only treated). 
When chemerin (10nM) was co-incubated with IL-1β (0-100ng/mL), a significant increase in NF-B activity was observed [Figure 1: aP < 
0.05, bP < 0.01, cP < 0.001 vs. IL-1β (100ng/mL) only treated, P < 0.001 vs. chemerin (10nM) only treated]. Data are mean ± SE of three 
experiments. Each experiment was carried out in three replicates. Group comparison by ANOVA (post hoc analysis: Tukey’s test).
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Figure 2: Chemerin increases endothelial cell adhesion molecules mRNA expression in HMEC-1 cells. Serum starved 
HMEC-1 cells were treated with chemerin (0-10nM) for 4 hours. Real-time quantitative RT-PCR analyses showed that mRNA expression of 
cell adhesion molecules, i.e. E-selectin, VCAM-1 and ICAM-1, were significantly up-regulated by chemerin in a concentration dependent 
manner at 4 hours (Figures 2A-2C: ***P < 0.001 vs. basal). Data are mean ± SE of three experiments. Each experiment was carried out in 
three replicates. Group comparison by ANOVA (post hoc analysis: Tukey’s test).
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Figure 3: Chemerin increases endothelial cell adhesion molecules protein expression in HMEC-1 cells. Serum starved 
HMEC-1 cells were treated with chemerin (0-10nM) for 12 and 24 hours. Densitometric analysis of western blots (cell protein lysates) of 
E-selectin, VCAM-1 and ICAM-1 immune complexes having normalized to β-actin, respectively, showed that protein expression of cell 
adhesion molecules, i.e. E-selectin, VCAM-1 and ICAM-1, were significantly increased by chemerin in a concentration dependent manner 
at 12 hours (Figures 3A-3C: *P < 0.05 vs. basal, ***P < 0.001 vs. basal) and 24 hours (Figures 3D-3F: *P < 0.05 vs. basal, **P < 0.01 vs. basal, 
***P < 0.001 vs. basal). Data are mean ± SE of three experiments. Each experiment was carried out in three replicates. Group comparison 
by ANOVA (post hoc analysis: Tukey’s test).
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Figure 4: Chemerin increases endothelial cell adhesion molecules protein secretion in HMEC-1 cells. Serum starved 
HMEC-1 cells were treated with chemerin (0-10nM) for 12 hours. Densitometric analysis of western blots (conditioned media) of E-selectin, 
VCAM-1 and ICAM-1 immune complexes having normalized to β-actin, respectively, showed that secretion of cell adhesion molecules, 
i.e. E-selectin, VCAM-1 and ICAM-1, were significantly elevated by chemerin in a concentration dependent manner at 12 hours (Figures 
4A-4C: *P < 0.05 vs. basal, **P < 0.01 vs. basal, ***P < 0.001 vs. basal). Data are mean ± SE of three experiments. Each experiment was 
carried out in three replicates. Group comparison by ANOVA (post hoc analysis: Tukey’s test).
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Figure 5: Chemerin and IL-1β co-incubation; synergistic increase in cell adhesion molecule expression. Serum starved 
HMEC-1 cells were treated with chemerin (3nM) with or without IL-1β (10ng/ml) for 12 hours. (A) Representative western blots of 
E-selectin, VCAM-1 and ICAM-1 and their respective β-actin. (B-D) Densitometric analysis of western blots (cell protein lysates) of 
E-selectin, VCAM-1 and ICAM-1 immune complexes having normalized to β-actin, respectively, showed that protein expression of cell 
adhesion molecules, i.e. E-selectin, VCAM-1 and ICAM-1, were synergistically increased when compared to chemerin or IL-1β, alone 
(Figures 5A-5D: ***P < 0.001 vs. basal, *P < 0.05 vs. chemerin or IL-1β alone, **P < 0.01 vs. chemerin or IL-1β alone). (E) When 
pre-incubated with BAY 11-7085 [(10μM), NF-ĸB inhibitor], chemerin (3nM) induced VCAM-1 protein expression was significantly 
attenuated (Figure 5E: ***P < 0.001). Data are mean ± SE of three experiments. Each experiment was carried out in three replicates. Group 
comparison by ANOVA (post hoc analysis: Tukey’s test).
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Figure 6: Chemerin stimulates monocyte-endothelial cell adhesion via NF-ĸB, MAPK and PI3K/Akt pathways. Serum 
starved chemerin (0-10nM) treated HMEC-1 cells were co-cultured with THP-1 cells for 2 hours. Chemerin enhanced monocyte-endothelial 
adhesion in a concentration dependent fashion (Figure 6A: *P < 0.05 vs. basal, **P < 0.01 vs. basal). Furthermore, pre-incubation for 1 
hour with BAY 11-7085 [(10μM), NF-ĸB inhibitor] or U0126 [(10μM), MAPK inhibitor] or SB202190 [(1 μM), p38 MAPK inhibitor] or 
LY294002 [(10 μM), PI3K/Akt inhibitor], prior to treatment with chemerin (10nM) for 2 hours, chemerin induced monocyte-endothelial 
adhesion was significantly negated [Figure 6A: *P < 0.05 vs. chemerin (10nM) only treated, **P < 0.01 vs. chemerin (10nM) only treated]. 
The number of adherent cells is directly proportional to the fluorescence detected by a fluorescence plate reader expressed as Relative 
Fluorescence Units (RFU). Figure 6B are representative fluorescent microscopy images, which were transferred using National Institutes 
of Health (USA) ImageJ software. Data are mean ± SE of three experiments. Each experiment was carried out in three replicates. Group 
comparison by ANOVA (post hoc analysis: Tukey’s test).
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positive correlations to various aspects of the metabolic 
syndrome. We have previously demonstrated significantly 
increased serum chemerin levels in women with polycystic 
ovary syndrome (PCOS) [20]; a dysmetabolic state of pro-
inflammation in women [21], associated with an increased 
risk of developing T2DM and cardiovascular disorders 
[22]. Furthermore, chemerin tissue expression levels are 
increased in periaortic and epicardial adipose tissue depots 
in subjects with atherosclerosis, implicating a paracrine 
mediated action of chemerin [12]. Similarly, Neves et al. 
demonstrated that chemerin plays an important role in 
molecular and cellular processes associated with vascular 
injury and dysfunction through vascular smooth muscle 
cells (VSMC) oxidative stress and inflammation in a 
ChemR23-inhibitable manner [23, 24]. Since endothelial 
cells are the first line of contact with circulating mediators 
of inflammation, it remains an important therapeutic 
target in both prevention and inhibiting the progression 
of cardiovascular disorders. In the present study, we 
report that chemerin activates a pivotal pro-inflammatory 
transcriptional regulator NF-кB in human endothelial 
cells. We also demonstrate that chemerin enhances 
expression and secretion of endothelial cell adhesion 
molecules (E-selectin, VCAM-1 and ICAM-1), and 
promotes monocyte-endothelial adhesion.
In vascular inflammatory responses, NF-κB 
signaling is an important regulator of endothelial cell 
adhesion molecules and initiator of atherosclerotic 
changes including vessel wall remodeling, as part of an 
inflammatory response [8]. In our experiments, in addition 
to chemerin induced NF-κB activation, a synergistic 
response was observed when chemerin was co-incubated 
with IL-1β. In vivo studies have demonstrated that IL-1β 
induced atherogenic action by enhancing expression of cell 
adhesion molecules, leading to recruitment of monocytes 
[24, 25]. This is very likely the reason for the enhanced 
effect observed when chemerin was co-incubated with 
IL-1β and similar findings have been reported by others 
using other cytokines; though the exact aetiology for 
this remains elusive. Cheshire et al. demonstrated the 
importance of cytokine induced synergistic activation 
of NF-кB in pro-inflammatory states resulting in potent 
activation of NF-кB-dependent gene expression including 
cell adhesion molecules [21]. Taken together with our 
findings, it is plausible to suggest that chemerin may be 
involved in the enhancement of endothelial activation in 
combination with other cytokines in a pro-inflammatory 
milieu.
In contrast, Provoost et al. demonstrated an 
opposing role for chemR23 signaling of inﬂammatory 
responses in the lungs, comparing chemR23 knockout 
(KO) mice with corresponding wild-type (WT) mice, 
depending on the context of traffic-related particulate 
matter. The chemR23 axis showed proinﬂammatory 
properties in a model of acute lung inﬂammation, in 
contrast to anti-inﬂammatory effects in a model of allergic 
airway inﬂammation [26]. Similarly, Laranjeira et al. 
also report anti-inflammatory properties for chemerin 
[27]. The underlying basis of these opposing activities of 
chemerin/ chemR23 signaling remains unclear. Various 
proteases can process prochemerin to bioactive chemerin. 
Thus, depending on the proteases that are present in the 
microenvironment/organ, diverse chemerin fragments may 
be produced with distinct pharmacological properties [26].
Of late, it is thought that deciphering NF-κB 
linked multiple signaling cross talk is critical in the 
identification of novel therapeutic targets in combating 
atherosclerosis and related pathologies. Activation of NF-
κB signaling involves and influences multiple signaling 
cascades including MAPK and PI3K/Akt pathways 
[28–31]. Our experiments demonstrated the involvement 
of MAPK and PI3K/Akt pathways in chemerin induced 
NF-κB activation. However, further research is needed 
to elucidate the interactions between these complex 
regulatory pathways.
NF-κB activation leads to transcription activation 
of gene promoter regions of cell adhesion molecules 
namely E-selectin, VCAM-1 and ICAM-1 [8]. Increased 
endothelial cell surface expression of adhesion molecules 
fosters the initiation of early atherosclerotic processes [19]. 
We found that chemerin induced a significant increase in 
protein levels of endothelial cell adhesion molecules. We 
also demonstrated an increase in secreted endothelial cell 
adhesion molecules in response to chemerin treatment. 
The circulating levels of these soluble receptors are 
considered as potential biomarkers predictive of the 
severity of cardiovascular disorders [32]. Circulating 
adhesion molecules have never been directly correlated 
with chemerin in clinical studies, thus our findings lay the 
platform for this to be performed.
Initiation, maintenance and progression of 
atherosclerotic changes are predominantly influenced by 
surface expression of cell adhesion molecules that have 
critical effects on inflammation and on the integrity of 
the vascular wall [33]. Interactions between circulating 
monocytes and endothelial cells lead to the initiation of 
early atherosclerotic changes [34]. Extending our findings 
to a functional monocyte-endothelial adhesion assay, we 
observed that endothelial cells treated with chemerin 
resulted in a significant increase of adhered monocytes. 
Our findings agree with previous reports that have 
reported chemerin induced adhesion with macrophages 
[34].
Endothelial recruitment and monocytes adhesion 
are the earliest detectable events in the pathogenesis of 
atherosclerosis. The initial steps of endothelium/leucocyte 
interactions are considered to involve selectins (E-, P-, L- 
selectin) and I-CAM, V-CAM are crucial for adhesion 
and migration of leucocytes into the sub-endothelium. 
So, the elevation of cell adhesive molecules is related 
to higher morbidity and these cytokines are considered 
as reliable biomarkers of endothelial activation and 
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inflammation in diabetes and obesity [35]. These dynamic 
relationships between chemerin and atherosclerosis may 
give meaningful contribution to the understanding of 
atherosclerosis pathogenesis in these states leading to 
early detection and potentially the development of novel 
therapies [36]. In summary, our novel in vitro findings 
demonstrate a direct mechanism linking chemerin-
induced NF-κB activation to functional changes in 
the endothelium. A limitation of this study is the lack 
of clinical evidence and in vivo animal data. Robust in 
vivo testing must be performed to fully understand the 
inflammatory properties of chemerin in ECs. Our data 
provide novel insights into chemerin vascular biology 
pertinent to atherosclerosis.
MATERIALS AND METHODS
Biochemicals and reagents
Full length recombinant human chemerin (2324-
CM-025) was obtained from R & D systems, Abingdon, 
UK; IL-1β peptide: Abcam, Cambridge, UK. BAY 11-
7085: Sigma-Aldrich, Gillingham, UK; U0126 (Promega, 
Southampton, UK); SB203580 (Merck Chemicals Ltd., 
Nottingham, UK); LY294002 (Merck Millipore, Watford, 
UK). E-selectin (sc-6940), ICAM-1 (sc-1511) and VCAM-
1 (sc-1504) antibodies: Santa Cruz Biotechnology, Inc., 
Heidelberg, Germany; β-actin antibody: Cell Signaling 
Technology, Danvers, USA.
Cell culture
HMEC-1 cells (Centre for Disease Control, Atlanta, 
USA) were cultured in MCDB media (Sigma-Aldrich, 
Gillingham, UK) supplemented with 10% Fetal Calf 
Serum (FCS) (Sigma-Aldrich, Gillingham, UK), 100IU/
ml penicillin (Sigma-Aldrich, Gillingham, UK), 100μg/
ml streptomycin (Sigma-Aldrich, Gillingham, UK), 5ml of 
200mM L-glutamine/500ml of media, 2μM hydrocortisone 
(Sigma-Aldrich, Gillingham, UK) – hydrocortisone works 
synergistically with epidermal growth factor to maintain 
normal colony morphology and growth of HMEC −1 
cells in culture [16], 2ng/ml epidermal growth factor (Life 
Technologies Ltd., Paisley, UK) at 37°C in 5% CO2/95% 
air. Prior to each experiment, cells were serum starved 
with 1% FCS overnight.
THP-1 cells (LGC, Teddington, UK) were cultured 
in RPMI 1640 media (Life Technologies Ltd., Paisley, 
UK) supplemented with 10% heat-inactivated FCS 
(Sigma-Aldrich, Gillingham, UK), 100 IU/ml penicillin 
(Sigma-Aldrich, Gillingham, UK), 100μg/ml streptomycin 
(Sigma-Aldrich, Gillingham, UK) and 2mM L-glutamine 
(Sigma-Aldrich, Gillingham, UK) and 10mM HEPES 
(Life Technologies Ltd., Paisley, UK) at 37°C in 5% 
CO2/95% air.
Transfection of HMEC-1 cells with NF-κB-Luc 
plasmid
HMEC-1 cells at 80-90% confluence were 
transfected with pcDNA3.1-NF-κB-Luc (Stratagene, 
LA Jolla, USA) using Lipofectamine reagent (Life 
Technologies Ltd., Paisley, UK). After allowing 24 hours 
of transfection time, cell media were replaced with MCDB 
131 media media (Sigma-Aldrich, Gillingham, UK) 
containing 10% FCS media (Sigma-Aldrich, Gillingham, 
UK) at a density of 3 × 105 per well in a 6-well plate. Cell 
lysates were collected, and luminescence was measured 
using a dual luciferase reporter assay system (Promega, 
Southampton, UK). For measuring transfection efficiency, 
a control plasmid with a luciferase gene insert was also 
transfected and luciferase activity was measured.
Total RNA extraction and cDNA synthesis
Total RNA was extracted from HMEC-1 cells 
Qiagen RNeasy Mini Kit according to the manufacturer’s 
guidelines (Qiagen, Crawley, UK). The purity of 
the extracted RNA was measured by a NanoDrop 
spectrophotometer. A set concentration of RNA was 
reverse transcribed into cDNA, by using Moloney murine 
leukemia virus reverse transcriptase (Fermentas, York, 
U.K.) and random hexamers (Promega, Southampton, 
U.K.) as primers, as previously described [17].
Reverse transcription polymerase chain reaction 
(RT-PCR)
Real-time quantitative PCR was performed as 
previously described [16]. Protocol conditions consisted 
of denaturation at 94°C for 1 minute, then 38 cycles of 
94°C for 30 seconds, 60°C for 45 seconds, and 72°C for 
30 seconds, followed by extension at 72°C for 7 minutes.
For analysis, quantitative amounts of genes of 
interest were standardised against the housekeeping 
gene GAPDH. The RNA levels were expressed as a 
ratio, using “Delta-delta method” for comparing relative 
expression results between treatments in real-time PCR 
[18]. The sequences of the sense and anti-sense primers 
used were:
E-selectin (198bp) 5’-CAGCCCCCGAAGGGTTT 
GGTG-3’ and 5’-TCCCGGAACTGCCAGGCTTGA-3’; 
VCAM-1 (189bp) β-actin (216bp) 5’-AGGTGACG 
AATGAGGGGACCACA-3’ and 5’-TCGGCTTCCC 
AGCCTCCAGA-3’; ICAM-1 (189bp) β-actin 
(126bp) 5’-GAGCTGAAGCGGCCAGCGAG-3’ and 
5’-AAGGGGCGGTGCTGCTTTCC-3’; GAPDH (185bp) 
β-actin (126bp) 5’-GAGTCAACGGATTTGGTCGT-3’ 
and 5’-GACAAGCTTCCCGTTCTCAG-3’.
10μl of the reaction mixture(s) were subsequently 
electrophoresed on a 1% agarose gel and visualised 
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by ethidium bromide, using a 1kb DNA ladder (Life 
Technologies Ltd., Paisley, UK) in order to estimate the 
band sizes. As a negative control for all the reactions, 
preparations lacking RNA or reverse transcriptase were 
used in place of the cDNA. RNAs was assayed from three 
independent biological replicates.
Sequence analysis
The PCR products from the cells were purified 
from the 1% agarose gel using the QIAquick Gel 
Extraction Kit (Qiagen, Crawley, UK). PCR products 
were then sequenced in an automated DNA sequencer, 
and the sequence data were analysed using Blast Nucleic 
Acid Database Searches from the National Centre for 
Biotechnology Information, confirming the identity of 
our products.
Western blotting
Cells grown in 12-well plates following various 
treatments were washed with ice cold phosphate 
buffered saline (PBS) solution and lysed in radio-
immunoprecipitation assay (RIPA) buffer (Merck 
Millipore, Watford, UK).
For experiments involving measurement of secreted 
proteins, the conditioned media (CM) was collected in 
sterile Eppendorf tubes, and spun down to remove the 
dead cells. Protein content in cell lysates and CM were 
quantified using Bicinchoninic Acid (BCA) assay kit 
(Sigma-Aldrich, Gillingham, UK). Protein lysates were 
prepared by mixing cell lysates/CM and SDS-sample 
buffer (5M urea, 0.17M SDS, 0.4M dithiothreitol and 
50mM Tris-HCl, pH 8.0), sonicated, boiled, centrifuged 
(5000rpm for 2 minutes) and then stored at −80ºC 
until use. 40μg of each sample were subjected to SDS-
polyacrylamide gel electrophoresis (10% resolving gel) 
and transferred to polyvinylidene difluoride (PVDF) 
membranes (Merck Millipore, Watford, UK). PVDF 
membranes were blocked in tris buffered saline (TBS) 
containing 0.1% Tween-20 and 5% bovine serum albumin 
(BSA) (Sigma-Aldrich, Gillingham, UK) for one hour at 
room temperature.
The PVDF membranes were then incubated with 
monoclonal primary mouse-anti-human antibodies for 
E-selectin, ICAM-1 and VCAM-1 (1:1000 dilutions 
in 0.1% Tween-20 and 5% BSA) overnight at 4°C. 
The membranes were washed thoroughly for 60 
minutes with TBS-0.1% Tween before incubation with 
the secondary anti-mouse horseradish peroxidase-
conjugated immunoglobulin (Dako, Ely, UK) [1:2000] or 
secondary anti-rabbit horseradish peroxidase-conjugated 
immunoglobulin (Dako, Ely, UK) [1:2000], respectively, 
for one hour at room temperature. Antibody complexes 
were visualized using chemiluminescence (ECL+GE 
Healthcare, Little Chalfont, UK). For standardization, 
the same membranes were stripped and reprobed with 
monoclonal primary rabbit-anti-human antibody for 
β-actin (1:10000 dilution).
Data analysis
The densities were measured using a scanning 
densitometer coupled to scanning software Scion Image™ 
(Scion Corporation, Frederick, USA). Standard curves 
were generated to ensure linearity of signal intensity 
over the range of protein amounts loaded into gel lanes. 
Comparisons of densitometric signal intensities for ASAA 
and β-actin were made only within this linearity range.
Monocyte-endothelial cell adhesion assay
Monocyte cell adhesion was studied using the 
Vybrant Cell Adhesion Assay Kit (Life Technologies Ltd., 
Paisley, UK). THP-1 monocytes were labelled with calcein 
acetoxymethyl ester (2.5μM final working concentration), 
swirled gently, and incubated at 37oC for 30 minutes. 
100μl/well of resultant suspension containing 5 × 105 cells 
was added to serum starved endothelial cells cultured in 
96-well plate at a final cell density of 0.5-2.0 × 106 cells 
per ml. After incubating at 37oC for 30 minutes, 75% of 
cell supernatant volume was aspirated out and discarded. 
Plate wells were washed twice with 200μl of assay buffer 
to remove non-adherent THP-1 monocytes. After removal 
of non-adherent cells, 100μl of assay buffer solution was 
added to each well, and fluorescence per well (excitation 
filter 485nm, emission filter 530nm) plate reading was 
measured using a fluorescence plate reader.
Statistical methods
Data are mean ± SE. Data were analysed by ANOVA 
using Tukey’s test to correct for multiple comparisons; 
GraphPad Prism 6; GraphPad Software, San Diego, USA. 
P < 0.05 was considered significant.
Abbreviations
T2DM = Type 2 Diabetes Mellitus; NF-κB = 
Nuclear factor kappa-light-chain-enhancer of activated B 
cells; MAPK = Mitogen-activated protein kinase; PI3K/
Akt = Phosphatidylinositol-4,5-bisphosphate 3-kinase/
Protein kinase B; E-selectin = Endothelial Selectin; 
VCAM-1 = Vascular Cell Adhesion Molecule-1; ICAM-1 
= Intracellular Adhesion Molecule-1; IL-1β = Interleukin 
1beta; RT-PCR = Reverse transcription polymerase 
chain reaction; PCOS = Polycystic Ovary Syndrome; 
VSMC = Vascular smooth muscle cells; EC = Endothelial 
cells; RIPA = Radio-immunoprecipitation assay; CM = 
Conditioned media; BCA = Bicinchoninic Acid; PVDF 
= Polyvinylidene difluoride; TBS = Tris buffered saline; 
BSA = Bovine serum albumin
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